RxDoctor Payments Data

April Price, PA

Physician Assistant · Salisbury, MDNPI 1740246420

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,554, 7.3 times the $213 reported in 2021. Among physician assistant clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,944in general payments, 2019–2025

Across 143 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$451
  • Biogen$332
  • UCB, Inc.$281
  • Lundbeck LLC$215
  • Lilly USA, LLC$146
  • Pfizer$117
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$2,944100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,944 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland →

Medicare billing

Part B allowed, 2024
$42,417
Medicare patients
315
Services billed
493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant20$37,685
Nurtec OdtRimegepant Sulfate22$34,523
QuliptaAtogepant16$16,686
Aimovig AutoinjectorErenumab-Aooe13$13,302
Levetiracetam25$383
Gabapentin24$348
Donepezil Hcl18$320
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$132
Topiramate28$128
Cephalexin18$118
Doxycycline Monohydrate11$105
Prednisone44$72
Azithromycin12$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$451$54,37136 claims
PfizerNurtec Odt$117$34,52322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Salisbury

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →